Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leu...
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2019-12-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 11
- Registration Number
- NCT01969695
- Locations
- 🇺🇸
University of Arizona Arthritis Center /ID# 101359, Tucson, Arizona, United States
🇺🇸Dartmouth-Hitchcock Med Ctr /ID# 92596, Lebanon, New Hampshire, United States
🇺🇸Hackensack Univ Med Ctr /ID# 101417, Hackensack, New Jersey, United States
A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2014-05-26
- Lead Sponsor
- AbbVie
- Registration Number
- NCT01969682
- Locations
- 🇺🇸
Site Reference ID/Investigator# 101416, Hackensack, New Jersey, United States
A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
- Conditions
- Interventions
- First Posted Date
- 2013-02-20
- Last Posted Date
- 2021-08-02
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 66
- Registration Number
- NCT01794507
- Locations
- 🇺🇸
University of Arizona Cancer Center - North Campus /ID# 117876, Tucson, Arizona, United States
🇺🇸Mayo Clinic /ID# 121495, Jacksonville, Florida, United States
🇦🇺Peter MacCallum Cancer Ctr /ID# 79553, Melbourne, Victoria, Australia
Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2013-02-20
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 117
- Registration Number
- NCT01794520
- Locations
- 🇺🇸
Medical College of Wisconsin /ID# 205229, Milwaukee, Wisconsin, United States
🇺🇸Mayo Clinic - Rochester /ID# 74994, Rochester, Minnesota, United States
🇺🇸Mayo Clinic - Scottsdale /ID# 75808, Scottsdale, Arizona, United States
Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma
- Conditions
- LymphomaRelapsed LymphomaRefractory LymphomaRelapsed and/or Refractory LymphomaRelapsed Ddiffuse Large B-Cell Lymphoma (DLBCL)Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Double-expressor Lymphoma (DEL)High-grade B-cell Lymphoma (HGBL)Double-hit Lymphoma (DHL)
- Interventions
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2021-05-06
- Lead Sponsor
- Curis, Inc.
- Target Recruit Count
- 106
- Registration Number
- NCT01742988
- Locations
- 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸University of Chicago Medicine, Chicago, Illinois, United States
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
- First Posted Date
- 2012-09-18
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 97
- Registration Number
- NCT01686555
- Locations
- 🇺🇸
Site Reference ID/Investigator# 89694, Clearwater, Florida, United States
🇺🇸Site Reference ID/Investigator# 124116, Miami Lakes, Florida, United States
🇺🇸Site Reference ID/Investigator# 78256, Overland Park, Kansas, United States
A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT01685892
- Locations
- 🇺🇸
UCSD Moores Cancer Center, La Jolla, California, United States
🇺🇸Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver, Colorado, United States
🇺🇸Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2012-09-11
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 49
- Registration Number
- NCT01682616
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine /ID# 71593, Chicago, Illinois, United States
🇺🇸North Shore University Hospital /ID# 71813, New Hyde Park, New York, United States
🇦🇺Peter MacCallum Cancer Ctr /ID# 70394, Melbourne, Victoria, Australia
A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2012-08-24
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT01671904
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸University of California San Diego Medical Center, La Jolla, California, United States
🇫🇷Hopital Saint Eloi, Montpellier, France
A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2021-08-02
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 60
- Registration Number
- NCT01594229
- Locations
- 🇺🇸
Johns Hopkins University /ID# 67345, Baltimore, Maryland, United States
🇺🇸Emory University Hospital /ID# 67349, Atlanta, Georgia, United States
🇺🇸Georgia Regents University /ID# 67342, Augusta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.